<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343421</url>
  </required_header>
  <id_info>
    <org_study_id>A5I16</org_study_id>
    <nct_id>NCT00343421</nct_id>
  </id_info>
  <brief_title>Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers</brief_title>
  <official_title>Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix®-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar® to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and immunogenicity of Pediacel® in infants&#xD;
      and toddlers when given at 2,3,4 and 12-18 months of age.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        -  To compare the post-dose 3 immunogenicity of Pediacel® to Infanrix®-IPV+Hib when both&#xD;
           are co-administered with Prevenar®.&#xD;
&#xD;
        -  To describe the post-dose 3 pertussis antibody responses.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To compare the post-dose 4 immunogenicity of Pediacel® to Infanrix®-IPV+Hib when both&#xD;
           are co-administered with Prevenar®.&#xD;
&#xD;
        -  To describe the safety after each vaccination following co-administration with&#xD;
           Prevenar®.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immunogenicity of PEDIACEL® and Infanrix®-IPV+Hib</measure>
    <time_frame>1 month post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide information concerning the safety after administration of PEDIACEL® and Infanrix®-IPV+Hib</measure>
    <time_frame>Entire study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">588</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEDIACEL co-administered with Prevenar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infanrix-IPV+Hib co-administered with Prevenar</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEDIACEL® and Prevenar®</intervention_name>
    <description>0.5 mL each, IM (opposite thigh)</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>PEDIACEL®: DT5aP-IPV-Hib 5-component Pertussis vaccine</other_name>
    <other_name>Prevenar®: Pneumococcal saccharide conj. vaccine, adsorbed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix®-IPV+Hib and Prevenar®</intervention_name>
    <description>0.5 mL each, IM (opposite thigh)</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Infanrix®-IPV+Hib: DTap, IPV and adsorbed conjugated Hib</other_name>
    <other_name>Prevenar®: Pneumococcal saccharide conj vaccine, adsorbed.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants 55 to 75 days old, inclusive on the day of first vaccination&#xD;
&#xD;
          -  Born at full term of pregnancy (&gt; 37 weeks)&#xD;
&#xD;
          -  Informed consent form signed by the parent(s) or the legal guardian&#xD;
&#xD;
          -  Parents or the legal guardian able to read and write in the local language&#xD;
&#xD;
          -  Parent(s) or the legal guardian able to attend all scheduled visits and to comply with&#xD;
             the study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of fever (defined as rectal body temperature ≥ 38.0°C) reported within the&#xD;
             last 72 hours&#xD;
&#xD;
          -  Moderate or severe acute illness with or without fever&#xD;
&#xD;
          -  Participation in another clinical trial in the 30 days preceding first study&#xD;
             vaccination&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present study period&#xD;
&#xD;
          -  Received diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b&#xD;
             or a pneumococcal vaccine separately or in combination prior to study vaccination&#xD;
&#xD;
          -  Received any vaccination in the 30 days preceding the first study vaccination and/or&#xD;
             is planning any vaccination within 6 weeks following any of the study vaccinations&#xD;
&#xD;
          -  Congenital or acquired humoral/cellular immunodeficiency or immunosuppressive therapy&#xD;
             such as long-term systemic corticosteroids therapy (≥ 2 mg/kg/day prednisone&#xD;
             equivalent for ≥ 14 days) in the previous 30 days&#xD;
&#xD;
          -  Systemic or local hypersensitivity to any of the study vaccine components (including&#xD;
             neomycin, streptomycin, polymyxin B and formaldehyde)&#xD;
&#xD;
          -  History of life-threatening reaction(s) (such as encephalopathy,&#xD;
             Hypotonic-Hyporesponsive Episode, rectal body temperature ≥ 40.0°C, convulsions with&#xD;
             or without fever) to any vaccine containing the same components as the study vaccines&#xD;
&#xD;
          -  Blood or blood-derived products (immunoglobulins) received since birth&#xD;
&#xD;
          -  Known Human immunodeficiency virus (HIV) seropositivity&#xD;
&#xD;
          -  Known thrombocytopenia or other bleeding disorder contraindicating intramuscular&#xD;
             vaccination&#xD;
&#xD;
          -  History of encephalopathy, seizures or progressive, evolving or unstable neurological&#xD;
             condition&#xD;
&#xD;
          -  Clinically significant findings on review of systems that might interfere with study&#xD;
             vaccination or which, in the opinion of the Investigator, would interfere with the&#xD;
             evaluation of the study vaccine/objectives or pose a health risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Days</minimum_age>
    <maximum_age>75 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Grimprel E, Wysocki J, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Immunogenicity and safety of fully liquid DTaP₅-IPV-Hib compared with DTaP₃-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study. Vaccine. 2011 Oct 6;29(43):7370-8. doi: 10.1016/j.vaccine.2011.07.078. Epub 2011 Jul 30.</citation>
    <PMID>21807056</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 21, 2006</study_first_submitted>
  <study_first_submitted_qc>June 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>Pneumococcal infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Tetany</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

